

Attorney Docket # 4061-27PUS

Express Mail #EV528956903US  
Patent**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re National Phase PCT Application of  
Stanka PERC et al.

Int'l PCT Serial No.: PCT/SI2003/000036

Int'l Filing Date:: October 16, 2003

For: Pharmaceutical Formulation of  
Olanzapine**INFORMATION DISCLOSURE STATEMENT**

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

S I R:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO/SB/08a. .

Also enclosed is a copy of the International Search Report.

In accordance with 37 C.F.R §§1.97(g) and (h), the filing of this Information Disclosure Statement should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserve(s) the right to prove that the date of publication is in fact different.

It is respectfully requested that the above information be considered by the Examiner and that the copy of the enclosed Form PTO/SB/08a be returned indicating that such information has been considered.

Respectfully submitted,  
COHEN, PONTANI, LIEBERMAN & PAVANE

By Kent H. Cheng  
Kent H. Cheng  
Reg. No. 33,849  
551 Fifth Avenue, Suite 1210  
New York, New York 10176  
(212) 687-2770

Dated: April 15, 2005

